RA CAPITAL MANAGEMENT, L.P. - 27 Apr 2026 SCHEDULE 13D/A Report for Climb Bio, Inc. Common Stock, par value $0.0001 per share (CLYM)

Quoteable Key Fact

"RA CAPITAL MANAGEMENT, L.P. disclosed 33% ownership in Climb Bio, Inc. Common Stock, par value $0.0001 per share (CLYM) on 27 Apr 2026."

Quick Takeaways

RA CAPITAL MANAGEMENT, L.P. filed SCHEDULE 13D/A for Climb Bio, Inc. Common Stock, par value $0.0001 per share (CLYM).
Disclosed ownership: 33%.
Date of event: 27 Apr 2026.

This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
You can verify ownership claims directly against the original SEC filing.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Name	Ownership	Shares Owned	shared voting power	Signature	Title	CIK
RA Capital Management, L.P.	33%	22,631,401	22,631,401	/s/ Peter Kolchinsky	By Peter Kolchinsky, Authorized Signatory	0001346824
Peter Kolchinsky	33%	22,631,401	22,631,401	/s/ Peter Kolchinsky	Peter Kolchinsky	0001384859
Rajeev Shah	33%	22,631,401	22,631,401	/s/ Rajeev Shah	Rajeev Shah	0001619841
RA Capital Healthcare Fund, L.P.	25%	17,123,763	17,123,763	/s/ Peter Kolchinsky	By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager	0001315082
RA Capital Nexus Fund III, L.P.	9.3%	5,346,247	5,346,247	/s/ Peter Kolchinsky	By RA Capital Nexus Fund III GP, LLC, its General Partner, By Peter Kolchinsky, Manager	0001883840
Sera Medicines, LLC	4.3%	2,479,872	2,479,872	/s/ Stephen Thomas	By Stephen Thomas, Chief Executive Officer